china-drug
BEIJING (Bloomberg):- A newly approved Chinese drug for Alzheimer's will start clinical trials in the United States and Europe next year as the country's first novel therapy for the incurable disease seeks global legitimacy.
Shanghai Green Valley Pharmaceutical Co plans to recruit around 2,046 patients with mild to moderate Alzheimer's for trials at 200 sites across North America, Europe and Asia Pacific for 18 months, the company's vice-president Li Jinhe said on Sunday (Dec 29).
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
